DR. JEROME ROTTER, M.D.
Medical Practice at Beverly Blvd, Los Angeles, CA
License number
California G27687
Category
Medical Practice
Type
Specialist
Address
Address
8700 Beverly Blvd, Los Angeles, CA 90048
Phone
(310) 967-1884
(310) 967-1744 (Fax)
(310) 967-1744 (Fax)
Personal information
See more information about JEROME ROTTER at radaris.comName
Address
Phone
14811 S Denker Ave, Gardena, CA 90247
2617 Greenfield Ave, Los Angeles, CA 90064
Yucca Valley, CA
14811 Denker Ave, Gardena, CA 90247
1540 10Th St, Manhattan Beach, CA 90266
Organization information
See more information about JEROME ROTTER at bizstanding.comJerome Rotter MD
8700 Beverly Blvd, Los Angeles, CA 90048
Industry:
Genetic Medicine, Internist
Phone:
(310) 423-6467 (Phone)
Jerome Israel Rotter
Professional information
See more information about JEROME ROTTER at trustoria.com
Method Of Haplotype-Based Genetic Analysis For Determining Risk For Developing Insulin Resistance And Coronary Artery Disease
Method Of Haplotype-Based Genetic Analysis For Determining Risk For Developing Insulin Resistance And Coronary Artery Disease
US Patent:
7141373, Nov 28, 2006
Filed:
Jun 16, 2003
Appl. No.:
10/463301
Inventors:
Kent D. Taylor - Ventura CA, US
Jerome I. Rotter - Los Angeles CA, US
Huiying Yang - Cerritos CA, US
Willa A. Hsueh - Pacific Palisades CA, US
Xiuqing Guo - Santa Monica CA, US
Leslie J. Raffel - Los Angeles CA, US
Mark O. Goodarzi - Los Angeles CA, US
Jerome I. Rotter - Los Angeles CA, US
Huiying Yang - Cerritos CA, US
Willa A. Hsueh - Pacific Palisades CA, US
Xiuqing Guo - Santa Monica CA, US
Leslie J. Raffel - Los Angeles CA, US
Mark O. Goodarzi - Los Angeles CA, US
Assignee:
Cedars-Sinai Medical Center - Los Angeles CA
The Regents of the University of California - Oakland CA
The Regents of the University of California - Oakland CA
International Classification:
C12Q 1/68, C12P 19/34, C07H 21/04
US Classification:
435 6, 435 912, 536 232, 536 235
Abstract:
Disclosed is a method for determining haplotypes useful for large-scale genetic analysis, within a genomic reference sequence of interest, for a human subpopulation. The method can applied to statistically evaluating the genotypes of subjects for any statistically significant association with a phenotype of interest, such as insulin resistance or coronary artery disease. Thus, also disclosed are a method of detecting a genetic predisposition in a Mexican-American human subject for developing insulin resistance and methods of detecting a lower than normal risk in a Mexican-American human subject for developing insulin resistance or coronary artery disease.
Methods Of Predicting Complication And Surgery In Crohn's Disease
Methods Of Predicting Complication And Surgery In Crohn's Disease
US Patent:
2012007, Mar 29, 2012
Filed:
Apr 8, 2010
Appl. No.:
13/263707
Inventors:
Jerome I. Rotter - Los Angeles CA, US
Kent D. Taylor - Ventura CA, US
Marla Dubinsky - Los Angeles CA, US
Stephan R. Targan - Santa Monica CA, US
Kent D. Taylor - Ventura CA, US
Marla Dubinsky - Los Angeles CA, US
Stephan R. Targan - Santa Monica CA, US
Assignee:
CEDARS-SINAI MEDICAL CENTER - Los Angeles CA
International Classification:
A61B 17/00, G01N 33/53, C12Q 1/68
US Classification:
128898, 435 611, 436501
Abstract:
The present invention relates to prognosing, diagnosing and treating an aggressive form of Crohn's disease characterized by rapid progression to complication and/or surgery from the time of diagnosis. In one embodiment, the prognosis, diagnosis and treatment is based upon the presence of one or more genetic risk factors.
Methods Of Predicting Medically Refractive Ulcerative Colitis (Mr-Uc) Requiring Colectomy
Methods Of Predicting Medically Refractive Ulcerative Colitis (Mr-Uc) Requiring Colectomy
US Patent:
2012005, Mar 1, 2012
Filed:
Dec 24, 2009
Appl. No.:
13/140874
Inventors:
Jerome I. Rotter - Los Angeles CA, US
Kent D. Taylor - Ventura CA, US
Stephan R. Targan - Santa Monica CA, US
Talin Haritunians - Encino CA, US
Dermot P. McGovern - Los Angeles CA, US
Xiuqing Guo - Santa Monica CA, US
Kent D. Taylor - Ventura CA, US
Stephan R. Targan - Santa Monica CA, US
Talin Haritunians - Encino CA, US
Dermot P. McGovern - Los Angeles CA, US
Xiuqing Guo - Santa Monica CA, US
Assignee:
CEDARS-SINAI MEDICAL CENTER - Los Angeles CA
International Classification:
A61K 38/12, A61K 31/56, C40B 40/06, A61B 17/00, C12Q 1/68, C40B 30/04
US Classification:
514 211, 435 611, 506 9, 506 16, 128898, 514179
Abstract:
Disclosed are methods of predicting the development of medically refractory ulcerative colitis (MR-UC) in a patient In one embodiment, disclosed is a method of prognosing ulcerative colitis in an individual by determining the presence or absence of one or more risk variants, where the presence of one or more risk variants is indicative of a severe and/or aggressive form of ulcerative colitis. In another embodiment, the severe form of ulcerative colitis is indicative of MR-UC.
Genetic Marker Test For Lupus
Genetic Marker Test For Lupus
US Patent:
7037651, May 2, 2006
Filed:
Jul 18, 2001
Appl. No.:
09/909317
Inventors:
Betty P. Tsao - Los Angeles CA, US
Rita M. Cantor - Rolling Hills Estates CA, US
Jerome I. Rotter - Los Angeles CA, US
Rita M. Cantor - Rolling Hills Estates CA, US
Jerome I. Rotter - Los Angeles CA, US
Assignee:
Cedars-Sinai Medical Center - Los Angeles CA
The Regents of the University of California - Oakland CA
The Regents of the University of California - Oakland CA
International Classification:
C12Q 1/68, C12P 19/34, C07H 21/04
US Classification:
435 6, 435 912, 536 232, 536 2431, 536 2433
Abstract:
Disclosed is a genetic testing method for diagnosing systemic lupus erythematosus (SLE) in a human subject. The method is related to amplifying nucleic acids from human tissue samples and detecting the presence or absence of variant alleles of a gene encoding poly(ADP-ribosyl)transferase expression (PARP), which are diagnostic of SLE or indicate a genetic predisposition for developing SLE. Also disclosed are useful oligonucleotide primers, primer sets and genetic testing kits for detecting a genetic predisposition for developing SLE.
Mutations In Nod2 Are Associated With Fibrostenosing Disease In Patients With Crohn's Disease
Mutations In Nod2 Are Associated With Fibrostenosing Disease In Patients With Crohn's Disease
US Patent:
2004005, Mar 18, 2004
Filed:
Jan 30, 2003
Appl. No.:
10/356736
Inventors:
Maria Abreu - Pacific Palisades CA, US
Kent Taylor - Ventura CA, US
Jerome Rotter - Los Angeles CA, US
Huiying Yang - Cerritos CA, US
Kazuhito Sugimura - Niigata, JP
Stephan Targan - Santa Monica CA, US
Kent Taylor - Ventura CA, US
Jerome Rotter - Los Angeles CA, US
Huiying Yang - Cerritos CA, US
Kazuhito Sugimura - Niigata, JP
Stephan Targan - Santa Monica CA, US
International Classification:
C12Q001/68
US Classification:
435/006000
Abstract:
The present invention provides a method of diagnosing or predicting susceptibility to a clinical subtype of Crohn's disease characterized by fibrostenosing disease by determining the presence or absence in an individual of a fibrostenosis-predisposing allele linked to a NOD2/CARD15 locus, where the presence of the fibrostenosis-predisposing allele is diagnostic of or predictive of susceptibility to the clinical subtype of Crohn's disease characterized by fibrostenosing disease. In a method of the invention, the clinical subtype of Crohn's disease can be, for example, characterized by fibrostenosing disease independent of small bowel involvement. The invention also provides a method of optimizing therapy in an individual by determining the presence or absence in the individual of a fibrostenosis-predisposing allele linked to a NOD2/CARD15 locus, diagnosing individuals in which the fibrostenosis-predisposing allele is present as having a fibrostenosing subtype of Crohn's disease, and treating the individual having a fibrostenosing subtype of Crohn's disease based on the diagnosis.
Method Of Diagnosing A Clinical Subtype Of Crohn's Disease With Features Of Ulcerative Colitis
Method Of Diagnosing A Clinical Subtype Of Crohn's Disease With Features Of Ulcerative Colitis
US Patent:
5916748, Jun 29, 1999
Filed:
Aug 15, 1996
Appl. No.:
8/689873
Inventors:
Stephan R. Targan - Santa Monica CA
Eric A. Vasiliauskas - Hermosa Beach CA
Scott E. Plevy - Tenafly NJ
Huiying Yang - Cerritos CA
Jerome I. Rotter - Los Angeles CA
Eric A. Vasiliauskas - Hermosa Beach CA
Scott E. Plevy - Tenafly NJ
Huiying Yang - Cerritos CA
Jerome I. Rotter - Los Angeles CA
Assignee:
Cedars-Sinai Medical Center - Los Angeles CA
International Classification:
C12Q 168, G01N 33564
US Classification:
435 6
Abstract:
The present invention provides a method of diagnosing a clinical subtype of Crohn's disease (CD) by determining whether perinuclear anti-neutrophil antibodies (pANCA) are present in a patient with CD, where the presence of pANCA indicates the clinical subtype of CD with features of ulcerative colitis (UC). The invention also provides a method of diagnosing a clinical subtype of CD by detecting an Arg. sup. 241 allele at an ICAM-1 locus in a patient with CD, where the Arg. sup. 241 allele indicates a clinical subtype of CD with features of ulcerative colitis. In addition, the invention provides a method of diagnosing a pANCA-positive subtype of CD by detecting an Arg. sup. 241 allele at an ICAM-1 locus in a patient with CD, where the Arg. sup. 241 allele indicates the pANCA-positive subtype of CD.
Methods Of Diagnosing Ulcerative Colitis And Crohn's Disease
Methods Of Diagnosing Ulcerative Colitis And Crohn's Disease
US Patent:
2014001, Jan 16, 2014
Filed:
Mar 26, 2012
Appl. No.:
14/007381
Inventors:
Kent D. Taylor - Ventura CA, US
Dermot P. McGovern - Los Angeles CA, US
Jerome I. Rotter - Los Angeles CA, US
Stephan R. Targan - Santa Monica CA, US
Talin Haritunians - Los Angeles CA, US
Dermot P. McGovern - Los Angeles CA, US
Jerome I. Rotter - Los Angeles CA, US
Stephan R. Targan - Santa Monica CA, US
Talin Haritunians - Los Angeles CA, US
Assignee:
CEDARS-SINAI MEDICAL CENTER - Los Angeles CA
International Classification:
G01N 33/68
US Classification:
435 792
Abstract:
The present invention relates to methods of prognosing inflammatory bowel disease (IBD) in an individual by determining the presence of at least one risk genetic variant and/or at least one risk serological marker. In one embodiment, the presence of risk serological marker ANCA is indicative of an aggressive form of ulcerative colitis. In another embodiment, the present invention relates to methods of diagnosing a Crohn's disease subtype in an individual, where the presence of risk variants and serological markers I2, OmpC and/or Cbir1 are indicative of the Crohn's disease subtype.
Methods Of Using Single Nucleotide Polymorphisms In The Tl1A Gene To Predict Or Diagnose Inflammatory Bowel Disease
Methods Of Using Single Nucleotide Polymorphisms In The Tl1A Gene To Predict Or Diagnose Inflammatory Bowel Disease
US Patent:
2010019, Jul 29, 2010
Filed:
Feb 26, 2008
Appl. No.:
12/528055
Inventors:
Jerome I. Rotter - Los Angeles CA, US
Kent D. Taylor - Ventura CA, US
Marla Dubinsky - Los Angeles CA, US
Stephan R. Targan - Santa Monica CA, US
Kent D. Taylor - Ventura CA, US
Marla Dubinsky - Los Angeles CA, US
Stephan R. Targan - Santa Monica CA, US
Assignee:
CEDARS-SINAI MEDICAL CENTER - Los Angeles CA
International Classification:
C12Q 1/68
US Classification:
435 6
Abstract:
This invention provides methods of diagnosing or predicting susceptibility to Inflammatory Bowel Disease by determining the presence or absence of genetic variants in the TL1A gene. In one embodiment, a method of the invention is practiced by determining the presence or absence of TL1A production following Fc-gamma-R activation. In another embodiment, the invention provides methods of treatment of inflammatory bowel disease by inhibition of TL1A.
Methods Of Using Smad3 And Jak2 Genetic Variants To Diagnose And Predict Inflammatory Bowel Disease
Methods Of Using Smad3 And Jak2 Genetic Variants To Diagnose And Predict Inflammatory Bowel Disease
US Patent:
2012004, Feb 16, 2012
Filed:
Jan 13, 2010
Appl. No.:
13/144376
Inventors:
Jerome I. Rotter - Los Angeles CA, US
Kent D. Taylor - Ventura CA, US
Stephan R. Targan - Santa Monica CA, US
Kent D. Taylor - Ventura CA, US
Stephan R. Targan - Santa Monica CA, US
Assignee:
CEDARS-SINAI MEDICAL CENTER - Los Angeles CA
International Classification:
C12Q 1/68, A61P 1/00, C07G 99/00
US Classification:
514789, 435 611
Abstract:
Disclosed are methods of diagnosing Inflammatory Bowel Disease by determining the presence or absence of genetic variants at SMAD3 and/or JAK2 loci. Provided is a method of diagnosing a Crohn's Disease subtype in an individual by determining the presence or absence of a risk variant at the SMAD3 and/or JAK2 loci.
Methods Of Using Fut2 Genetic Variants To Diagnose Crohn's Disease
Methods Of Using Fut2 Genetic Variants To Diagnose Crohn's Disease
US Patent:
2013013, May 30, 2013
Filed:
Jan 14, 2011
Appl. No.:
13/521622
Inventors:
Dermot P. McGovern - Los Angeles CA, US
Jerome I. Rotter - Los Angeles CA, US
Stephan R. Targan - Santa Monica CA, US
Kent D. Taylor - Ventura CA, US
Xiuqing Guo - Santa Monica CA, US
Jerome I. Rotter - Los Angeles CA, US
Stephan R. Targan - Santa Monica CA, US
Kent D. Taylor - Ventura CA, US
Xiuqing Guo - Santa Monica CA, US
Assignee:
CEDARS-SINAI MEDICAL CENTER - Los Angeles CA
International Classification:
C12Q 1/68
US Classification:
424 934, 506 2
Abstract:
The present invention relates to prognosing, diagnosing and treating of Crohn's disease. The invention also provides prognosis, diagnosis, and treatment that are based upon the presence of one or more genetic risk factors at the FUT2 genetic locus.